home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

21CFR Part 11 and Harmonization with 21 CFR Part 812 for Medical Device Trials

 
  August 08, 2012  
     
 
ComplianceOnline, Online Event
2012-08-23


Why Should You Attend:

Conducting clinical trials in a rapidly evolving electronic environment presents a unique challenge to the medical device industry where not only quality (GLP/GMP) plays an essential role – but collecting accurate, maintaining viable data (GCP) as part of continuous process improvement (while mitigating risk) is an essential and critical component of the development paradigm.

The complexity of medical device trials require adherence to 21 CFR Part 11 and Predicate Rules and must work in concert with 21 CFR 832.40. Additionally, many hybridized trials cross into the arena of Proof of Concept to allocate resources to devices and as well as biosimilars as part of the new of investigational products.

This session will review the dynamic changes in the conduct of clinical trials that extend beyond the GxP area with the use of lab information systems requiring computer validation and Software Development Life Cycle (SDLC) considerations. Participants will gain valuable insight into the regulatory requirements and how device trials have traditionally differed from pharmaceutical clinical trials.

Areas Covered in the Seminar:

This webinar will provide a firm foundation into what type of Medical Device trials trail-blaze across the traditional clinical activities which require additional compliance for Electronic Records:

  • Review 21 CFR Part 11 and the Predicate Rule;
  • Review 21 CFR 832.40;
  • Briefly overview actual case studies of what went wrong, how the risk of both financial and criminal liability could have been avoided through proper  response to Warning Letters;
  • Brief history on the Medical Device Safety Act, Social Media / Patient Reported Outcomes and pending legislation that will impact the medical device, generics as well as biosimilar trials.
Event Details:
 
Date:                    August 23, 2012
Time:                    10:00 AM-11:00 AM PDT
Cost:                    $249 per attendee per computer terminal
Registration:         SIgn-Up on-line now.  Add to your shopping cart.

 
 
Organized by: ComplianceOnline
Invited Speakers:

Darlene (Dar) Douglas, is a Principal Researcher for Mentor Demographics and a Primary Contributor to the National Institute of Health Cancer Bioinformatic Grid (caBIG). She has a proven track record of successfully achieving timely global regulatory approvals, initiating and effectively managing clinical investigations as well as corrective active programs. Dar has also participated in the Compilation of the Parke-Davis/Pfizer Validation Master Plan (VAMPIRE). She shares unique insights gained from fifteen years experience in clinical trial conduct, validation, quality control, data management systems, post approval market surveillance, supplier management and regulatory compliance in the areas of biopharmaceuticals, medical devices and public utility/power generation industries.

 
Deadline for Abstracts: 2012-08-23
 
Registration: http://www.complianceonline.com/ecommerce/control/trainingFocus/~product_id=702412?channel=hummolgen
E-mail: referral@complianceonline.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.